Disease Free Survival among Molecular Subtypes of Early Stage Breast Cancer between 2001 and 2010 in Iran

  • Najafi, Behrouz (Hematology and Oncology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science) ;
  • Anvari, Saeid (Hematology and Oncology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science) ;
  • Roshan, Zahra Atrkar (Hematology and Oncology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science)
  • Published : 2013.10.30


Background: Breast cancer is the most common cancer among women. Molecular subtypes are important in determining prognosis. This study evaluated five-year disease-free survival among four molecular subtypes in patients with early stages of breast cancer. Materials and Methods: In this retrospective descriptive-analytical study, information on patients with breast cancer between 2001-2010 was evaluated. Five hundred ninety two patients in the early stages of breast cancer (stages 1 and 2) were selected to undergo anthracycline-based chemotherapy. Relapse, death or absence (censor) were considered as the end of the study. Patients based on ER, PR and HER-2 expression were divided into four subtypes (luminal A, luminal B, HER-2 enriched and triple negative). Information based upon questionnaire was analysed. To show the patients survival rate, life table and Kaplan-Meyer methods were used, and for comparing mean survival among different groups, the Log-Rank test was utilized. Results: Mean age at diagnosis was $47.9{\pm}9.6$. Out of the 592 patients, 586 were female (99%) and 6 were male (1%). Considering breast cancer molecular subtypes, 361 patients were in the luminal A group (61%), 49 patients in the luminal B group (8.3%), 48 patients in the HER-2 enriched group (8.1%) and 134 in the triple negative group (22.6%). Mean disease-free survival was 53.7 months overall, 55.4 months for the luminal A group, 48.3 months for the luminal B group, 43 months for the HER-2enriched group and 54.6 months for the triple negatives. Disease free survival differed significantly among the molecular subtypes (p value=0.0001). Conclusions: The best disease-free survival rate was among the luminal A subgroup and the worst disease-free survival rate was among the HER-2 enriched subgroup. Disease free survival rate in the HER-2 positive groups (luminal B and HER-2 enriched) was worse than the HER-2 negative groups (luminal A and triple negative).


Breast cancer;molecular subtypes;disease free survival rate;early stages;anthracycline chemotherapy


  1. Caudle AS, Yu TK, Tucker SL, et al (2012). Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res, 14, 83.
  2. Allred DC, Harvey JM, Berardo M, Clark GM (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol, 2, 155-68.
  3. Bair E, Tibshirani R (2004). Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol, 4, 108.
  4. Bennis S, Abbass F, Akasbi Y, et al (2012). Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes, 5, 436.
  5. Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 5, 1000279.
  6. Carey LA, Dees EC, Sawyer L, et al (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34.
  7. Chen XS, Ma CD, Wu JY, et al (2010). Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori, 96, 103-10.
  8. Haghighat S, ME Akbari ME, Ghaffari S, Yavari P (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac Cancer Prev, 13, 5525-8.
  9. Jana D, Mandal S, Mukhopadhyay M, et al (2012). Prognostic Significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pac J Cancer Prev, 13, 3851-5.
  10. Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR (1998). Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol, 110, 758-64.
  11. Kadivar M, Mafi N, Joulaee A, Shamshiri A, Hosseini N (2012). Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women. Asian Pac Cancer Prev, 13, 1881-6.
  12. Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013). Association of immunoistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev, 14, 3223-8.
  13. King WJ, Greene GL (1984). Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature, 307, 745-7.
  14. Millar EK, Graham PH, O'Toole SA, et al (2009). Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol, 27, 4701-8.
  15. Noh JM, Choi DH, Huh SJ, et al (2011). Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer, 14, 46-51.
  16. Prat A, Parker JS, Karginova O, et al (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res, 12, 68.
  17. Ross JS, Fletcher JA, Bloom KJ, et al (2004). Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379-98.
  18. Voduc KD, Cheang MCU, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. JCO, 28,1684-91.
  19. Rouzier R, Perou CM, Symmans WF, et al (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 11, 5678-85.
  20. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
  21. Su Y, Zheng Y, Zheng W, et al (2010). Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer, 11, 292.
  22. Webster LR, Lee SF, Ringland C, et al (2008). Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Clin Cancer Res, 14, 6625-33.

Cited by

  1. Estimation of the Cure Rate in Iranian Breast Cancer Patients vol.15, pp.12, 2014,
  2. Breast Cancer Recurrence According to Molecular Subtype vol.15, pp.14, 2014,
  3. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes vol.15, pp.15, 2014,
  4. Five Year Survival of Women with Breast Cancer in Yazd vol.15, pp.16, 2014,
  5. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014,
  6. Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials vol.15, pp.5, 2014,
  7. Demographic Survey of Four Thousand Patients with 10 Common Cancers in North Eastern Iran over the Past Three Decades vol.15, pp.23, 2015,
  8. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015,
  9. Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival vol.20, pp.1, 2018,
  10. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran vol.14, pp.1, 2019,